. 2022 May 8;10(5):736. doi: 10.3390/vaccines10050736

Table 6.

R_o of SARS-CoV-2 that COVID-19 vaccination programs could block by achieving 70%, 80%, and 90% vaccination coverage, without infections among vaccinated individuals.

Vaccine	R_o of SARS-CoV-2 Blocked by COVID-19 Vaccination Programs Achieving 70%, 80%, and 90% Vaccination Coverage ^a
	Vaccination Coverage			Vaccination Coverage			Vaccination Coverage
	70%	80%	90%	70%	80%	90%	70%	80%	90%
	Ancestral Variant			Delta Variant			Omicron Variant
	R_o	R_o	R_o	R_o	R_o	R_o	R_o	R_o	R_o
Moderna	2.81	3.79	5.81	2.75	3.68	5.52	1.51	1.62	1.76
Pfizer/BioNTech	2.51	3.21	4.42	2.43	3.05	4.10	1.45	1.54	1.66
Sputnik	2.51	3.21	4.42	2.47	3.13	4.26	1.45	1.54	1.66
Novavax	2.39	2.98	3.95	2.35	2.91	3.82	1.43	1.52	1.63
Covaxin	2.04	2.40	2.92	2.02	2.36	2.84	1.36	1.44	1.52
Oxford/Astra-Zeneca	1.79	2.02	2.31	1.93	2.23	2.64	1.34	1.40	1.48
Sinopharm	1.91	2.19	2.58	1.88	2.16	2.52	1.32	1.39	1.46
Janssen	2.02	2.36	2.84	1.81	2.05	2.36	1.30	1.36	1.42
CoronaVac	1.49	1.60	1.73	1.47	1.58	1.71	1.20	1.24	1.28
Convidecia	1.77	1.98	2.26	1.75	1.95	2.22	1.18	1.21	1.25
AstraZeneca (AZ 3D)				2.91	4.01	6.42	2.04	2.40	2.92
Pfizer (PF 3D)				2.97	4.14	6.81	2.17	2.60	3.26

^a R_o values obtained for levels of effectiveness in preventing SARS-CoV-2 infection for all vaccines [8] (Table 1), and effectiveness in preventing symptomatic infection for AZ 3D and PF 3D vaccination [28].